(1) Chengdu Sennuo Biotech is a listed company.
(2) Business products: pharmaceuticals.
(3) Business scope: research on APIs, injections, tablets, capsules, and granules; production of APIs and freeze-dried powder for injections. ...Sales of products produced by the company; technology transfer (excluding transfer of patented technology, etc.) and technical consulting; import and export of goods and technology (except for import and export businesses expressly prohibited by the state). (The above business scope does not include items that are expressly prohibited or restricted by national laws, administrative regulations, or decisions of the State Council. Those that require special approval must be operated with a license or approval document).
Extended information:
(1) Chengdu Sennuo Biopharmaceutical Co., Ltd. is affiliated to Chengdu Sennuo Biotechnology Co., Ltd., established in October 2004, and is a high-tech enterprise in Sichuan Province. Technical certification enterprise, located in the Industrial Concentrated Development Zone of Dayi County, Chengdu City, covering an area of ??120 acres, with total assets of 150 million; it has nearly 320 employees, 265 with a college degree or above, and 8 with a graduate degree or above, among whom are engaged in peptide research and development There are 26 people working, 10 with technical titles and 20 with intermediate technical titles. The company has an API production workshop that complies with national GMP certification and a comprehensive preparation workshop for multiple dosage forms. It is a first-class domestic professional enterprise in the development, production and export of polypeptide drugs and one of the leaders in the field of polypeptide drugs in my country.
(2) Chengdu Sennuo Biotechnology Co., Ltd. is a high-tech enterprise with core technologies of peptide synthesis and modification. It has advanced and efficient peptide drug process research and development and large-scale production capabilities.
The company's main business is the independent research and development, production and sales of polypeptide APIs and preparations with large market capacity and strong competitiveness at home and abroad. At the same time, the company relies on the research and development and large-scale production of polypeptide drugs. With its technological advantages in the field, it provides domestic and foreign pharmaceutical companies with innovative pharmaceutical research services on peptides, customized production services for peptide products, and technology transfer services for peptide drug production. In addition, the company also provides processing of small molecule chemical drug levosimendan preparations and production, export and sales of levosimendan raw materials.
(3) The company has a full-process R&D pipeline and a full-industry chain platform for peptide APIs and preparations, and can provide peptide innovative drugs and generic drugs with process route design, small trials, pilot trials, and processes. Pharmaceutical research services such as validation and quality research, as well as full-chain customized production services for APIs and preparations required for drug R&D and commercial production, covering the complete drug development cycle from drug discovery, preclinical research, to clinical trials and marketing. . Relying on its core technological advantages in peptide synthesis and modification, the company has gained high visibility and recognition in the field of peptide drug R&D and production. It has provided 30 Pharmaceutical research and customized production services for the remaining projects, among which one innovative peptide drug has been approved for marketing and entered the commercialization stage, and another seven innovative peptide drugs have entered the clinical trial stage.